APA (7th ed.) Citation

Khatri, A., Dutta, S., Marbury, T. C., Preston, R. A., Rodrigues, L., Wang, H., . . . Menon, R. M. (2017). Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment. Clinical pharmacokinetics, 56(2), 153-163. https://doi.org/10.1007/s40262-016-0429-9

Chicago Style (17th ed.) Citation

Khatri, Amit, Sandeep Dutta, Thomas C. Marbury, Richard A. Preston, Lino Rodrigues, Haoyu Wang, Walid M. Awni, and Rajeev M. Menon. "Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment." Clinical Pharmacokinetics 56, no. 2 (2017): 153-163. https://doi.org/10.1007/s40262-016-0429-9.

MLA (9th ed.) Citation

Khatri, Amit, et al. "Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment." Clinical Pharmacokinetics, vol. 56, no. 2, 2017, pp. 153-163, https://doi.org/10.1007/s40262-016-0429-9.